Literature DB >> 2887041

Treatment of acute pancreatitis with beta-adrenergic agonist drugs.

M H Harvey, K R Wedgwood, H A Reber.   

Abstract

An increase in microvascular permeability may be important in the pathogenesis of acute pancreatitis. beta-adrenergic receptor agonist drugs are known to inhibit the increase in microvascular permeability induced by histamine and related vasoactive substances. These inflammatory mediators have been shown to be released during the course of experimental and human pancreatitis. We investigated the effect of isoproterenol and terbutaline sulfate on the development of acute edematous (AEP) and acute hemorrhagic (AHP) pancreatitis in a feline model of biliary pancreatitis. When given at the time of pancreatic insult, isoproterenol prevented the development of both AEP and AHP. Both isoproterenol and terbutaline sulfate reduced the severity of pancreatic inflammation, even when given up to 12 hours after the onset of AEP. Although neither drug was effective in treating established AHP, our findings suggest that, if given early in the course of the disease, they may be useful in preventing the progression of AEP to AHP.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2887041

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  3 in total

1.  A study of the time course of conversion of edematous to hemorrhagic pancreatitis.

Authors:  N D Karanjia; S M Singh; V Porter-Fink; A L Widdison; H A Reber
Journal:  Int J Pancreatol       Date:  1991-02

2.  Benefits of various dextrans after delayed therapy in necrotizing pancreatitis of the rat.

Authors:  J Schmidt; K Huch; K Mithöfer; H G Hotz; H P Sinn; H J Buhr; A L Warshaw; C Herfarth; E Klar
Journal:  Intensive Care Med       Date:  1996-11       Impact factor: 17.440

3.  Penetration of lanthanum through the main pancreatic duct epithelium in cats following exposure to infected human bile.

Authors:  T Arendt
Journal:  Dig Dis Sci       Date:  1991-01       Impact factor: 3.199

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.